%0 Journal Article
%T 间充质干细胞治疗薄型子宫内膜的研究进展<br>Research Progress of Mesenchymal Stem Cells in the Treatment of Thin Endometrium
%A 常媛媛
%A 石润茜
%A 张建芳
%A 张媛媛
%J Advances in Clinical Medicine
%P 14351-14356
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.1392007
%X 薄型子宫内膜(thin endometrium, TE)的定义目前尚无统一共识，多数研究将新鲜周期中人绒毛膜促性腺激素(human chorionic gonadotropin, hCG)注射日或复苏周期中孕酮开始日的内膜厚度 ≤ 7 mm定义为薄型子宫内膜，TE发生率大约为试管周期的2%~5%。TE可能和患者年龄、宫腔操作史和宫腔感染等有关，临床尚无确切有效的治疗方法。间充质干细胞(mesenchymal stem cells, MSCs)是一类具有自我更新和多向分化潜能特征的成体干细胞，MSCs通过免疫调节、归巢、旁分泌和多向分化潜能等途径促进子宫内膜增生恢复，在薄型子宫内膜治疗方面有巨大的应用潜能。本文将不同类型间充质干细胞治疗薄型子宫内膜的研究进行归纳总结，以期为临床治疗提供思路和方法。<br />
There is currently no unified consensus on the definition of thin endometrium (TE), and most stud-ies define it as thin endometrium with an endometrial thickness ≤ 7mm on the day of injection of human chorionic gonadotropin (hCG) in the fresh cycle or the day of progesterone start in the resus-citation cycle. The incidence of TE is approximately 2%~5% of the in vitro cycle. TE may be related to the patient’s age, history of uterine cavity surgery, and uterine cavity infection, and there is no definite and effective clinical treatment method. Mesenchymal stem cells (MSCs) are adult stem cells with self-renewal, rapid proliferation, and pluripotent differentiation potential. MSCs can pro-mote the recovery of endometrial hyperplasia through immune regulation, homing, paracrine, and pluripotent differentiation potential, and have enormous application potential in the treatment of thin endometrium. This article summarizes the research on the treatment of thin endometrium with different types of mesenchymal stem cells, in order to provide ideas and methods for clinical treatment.
%K 薄型子宫内膜，辅助生殖，间充质干细胞<br>Thin Endometrium
%K Assisted Reproduction
%K Mesenchymal Stem Cells
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=72245